Non-selective {beta}-blockers are associated with improved survival in patients with ascites listed for liver transplantation

Conclusions
NSBB in patients with ascites and refractory ascites listed for liver transplantation are not detrimental, and instead are associated with reduced waitlist death. Our findings argue that NSBB are safe and may confer benefit in patients with ascites complicating end-stage liver disease.

Source: Gut - June 9, 2015 Category: Gastroenterology Authors: Leithead, J. A., Rajoriya, N., Tehami, N., Hodson, J., Gunson, B. K., Tripathi, D., Ferguson, J. W. Tags: Hepatic cancer Hepatology Source Type: research